prod:prod_dcx-login
Xpert® C. difficile BT
Detection of toxigenic C. difficile with binary toxin call out and presumptive identification of the epidemic 027 strain in 43 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXCDIFFBT-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Single Use Disposable Swab (Pack of 120)
SDPS-120
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- Clostridioides difficile (C. difficile) is amongst the most frequently reported micro-organisms in healthcare associated infections in Europe1
- It is associated with an increase in length of hospital stay, high morbidity and mortality resulting in both societal and financial burden2
- Highly virulent (027-NAP1-BI) strains have caused outbreaks of severe diseasae in Europe and North America and are often resistant to fluoroquinolones3
- Although the accurate and rapid diagnosis of C. difficile is essential for effective and timely treatment, this remains an unmet clinical need4
1 Viprey, V. F., Granata, G., & Vendrik, K. (n.d.). European survey on the current surveillance practices, management ... https://www.journalofhospitalinfection.com/article/S0195-6701(22)00365-6/fulltext.
2 Tschudin-Sutter S, et al. Guidance document for prevention of C. difficile infection in acute healthcare settings. Clin Microbiol Infect 2018;24:1051
3 Markovska, R et al. Clostridioides difficile, a new suberbug, Microorganisms 2023, 11, 845. https://doi.org/10.3390/microorganisms11040845
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.
2 Tschudin-Sutter S, et al. Guidance document for prevention of C. difficile infection in acute healthcare settings. Clin Microbiol Infect 2018;24:1051
3 Markovska, R et al. Clostridioides difficile, a new suberbug, Microorganisms 2023, 11, 845. https://doi.org/10.3390/microorganisms11040845
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.
The Solution
- Xpert C. difficile BT provides detection and differentiation of Clostridioides difficile & the epidemic 027 strain, with a callout for binary toxin, in 43 minutes from unformed stool specimens
- Fast detection and differentiation of Clostridioides difficile & the epidemic presumptive 027 strain supports patient management decisions, enables timely and appropriate treatment, and supports infection control and outbreak prevention measures4
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
*These outcomes have been reported in the literature
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
*These outcomes have been reported in the literature
The Impact
st and accurate detection of toxigenic C. difficile is essential to aid diagnostic assessment, support bed management and help reduce opportunities for transmission and outbreaks. It has been associated with*:
– 45% reduced empiric therapy5
– 48% reduced isolation days6
– 45% reduced empiric therapy5
– 48% reduced isolation days6
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
Related Products
Xpert SA Nasal Complete
Detection of S. aureus and MRSA in about 65 minutes
Xpert Norovirus
Fast detection of Norovirus GI & GII with results available in 90 minutes
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 50 minutes
Xpert MRSA NxG
Accurate and fast on-demand PCR testing for MRSA surveillance in 70 minutes or less
Xpert MRSA/SA Blood Culture
MRSA and S. aureus detection from gram-positive blood culture samples in 62 minutes
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections in 62 minutes
Xpert vanA/vanB
Rapid VRE screening for active prevention, control, and outbreak management in around 48 minutes